Who are mOPV2 at 6 and 8 weeks of age's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): mOPV2 at 6 and 7 weeks of age, mOPV type 2, Rotavirus Vaccine (ROTARIX), Live attenuated HAV vaccine, Zostavax vaccine, mOPV1.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mopv2-at-6-and-8-weeks-of-age.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

mOPV2 at 6 and 8 weeks of age — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

mOPV2 at 6 and 8 weeks of age (mOPV2 at 6 and 8 weeks of age) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated vaccine. Area: Immunology / Infectious Disease.

marketed Live attenuated vaccine Poliovirus type 2 Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

mOPV2 at 6 and 8 weeks of age (mOPV2 at 6 and 8 weeks of age) — Centers for Disease Control and Prevention. mOPV2 is a live attenuated oral polio vaccine that stimulates immune responses against poliovirus type 2 to prevent poliomyelitis infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
mOPV2 at 6 and 8 weeks of age TARGET	mOPV2 at 6 and 8 weeks of age	Centers for Disease Control and Prevention	marketed	Live attenuated vaccine	Poliovirus type 2
mOPV2 at 6 and 7 weeks of age	mOPV2 at 6 and 7 weeks of age	Centers for Disease Control and Prevention	marketed	Live attenuated vaccine	Poliovirus type 2
mOPV type 2	mOPV type 2	University of Chile	marketed	Live attenuated vaccine	Poliovirus type 2
Rotavirus Vaccine (ROTARIX)	Rotavirus Vaccine (ROTARIX)	International Centre for Diarrhoeal Disease Research, Bangladesh	marketed	Live attenuated vaccine
Live attenuated HAV vaccine	Live attenuated HAV vaccine	Sinovac Biotech Co., Ltd	marketed	Live attenuated vaccine
Zostavax vaccine	Zostavax vaccine	Oklahoma Medical Research Foundation	marketed	Live attenuated vaccine	Varicella-zoster virus (VZV)
mOPV1	mOPV1	Aga Khan University	marketed	Live attenuated vaccine	Poliovirus type 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated vaccine class)

GlaxoSmithKline · 19 drugs in this class
Merck Sharp & Dohme LLC · 11 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
PATH · 5 drugs in this class
Sanofi · 5 drugs in this class
Bandim Health Project · 5 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Beijing Center for Disease Control and Prevention · 2 drugs in this class
Aga Khan University · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). mOPV2 at 6 and 8 weeks of age — Competitive Intelligence Brief. https://druglandscape.com/ci/mopv2-at-6-and-8-weeks-of-age. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab